Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03203642

Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD

ADPKD Clinical Trial

Official title:
A Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects With Autosomal Dominant Polycystic Kidney Disease

Clinical Trial Summary

The goal of the study was to compare and evaluate safety and efficacy of tesevatinib 50 milligrams (mg) versus placebo in participants with autosomal dominant polycystic kidney disease (ADPKD).

Clinical Trial Description

Safety and efficacy of 50 mg tesevatinib in comparison to placebo in participants with ADPKD was assessed. The primary purpose of this study was focused on evaluating the change from Baseline in height-adjusted total kidney volume (htTKV) as measured by magnetic resonance imaging (MRI) at Months 12, 18, and 24, and 30 days post-dose in participants with ADPKD treated with tesevatinib or placebo. If eligible for the study participation, participants were randomly assigned to either investigational treatment group or placebo group. Treatment group received 50 mg tesevatinib once daily for 24 months and control group received the placebo once daily for 24 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03203642
Study type Interventional
Source Sanofi
Contact
Status Completed
Phase Phase 2
Start date October 12, 2017
Completion date January 25, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04310319 - Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt N/A
Completed NCT02776241 - Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease N/A
Terminated NCT04152837 - Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Phase 3
Completed NCT03717883 - ADPKD Alterations in Hepatic Transporter Function
Recruiting NCT05014178 - Kidney Sodium Functional Imaging
Recruiting NCT05521191 - A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease Phase 1
Terminated NCT04064346 - Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease Phase 3
Recruiting NCT04338048 - Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study
Not yet recruiting NCT06100133 - Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester? Phase 2
Completed NCT01632605 - The Vienna RAP Pilot Study N/A
Terminated NCT03918447 - A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON Phase 3
Recruiting NCT06416761 - Genetics in the Progression of Nephropathies
Not yet recruiting NCT05373264 - HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life Phase 3
Recruiting NCT06085807 - Genetic Testing in Autosomal Dominant Polycystic Kidney Disease
Completed NCT01853553 - Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 3
Completed NCT04472624 - Short Term Induction of Ketosis in PKD N/A
Not yet recruiting NCT03764605 - Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease Phase 3
Completed NCT04680780 - Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD) N/A
Completed NCT02161068 - Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping
Active, not recruiting NCT03273413 - Statin Therapy in Patients With Early Stage ADPKD Phase 4